AK
ALK-Abelló A/S
AKBLF · OTC
$32.47 +0.00% (+$0.00)
Market Cap 42.6B kr
P/E Ratio 31.46x
Div. Yield 0.77%
ROE 20.76%
Bulios Fair Price
$22.8
29.8% downside
Current Price
$32.47
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AKBLF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
42 /100
Fair PEG 0.77x
P/S 6.25x
P/B 6.16x
Growth
91 /100
Growing Rev. growth 11.76%
FCF growth 190.06%
Book val. growth 17.26%
Profitability
100 /100
Strong Net margin 19.86%
Op. margin 26.72%
FCF margin 27.60%
Quality
86 /100
Excellent ROE 20.76%
ROA 13.98%
Asset turnover 0.70x
Debt
100 /100
Low Current ratio 3.46x
Net debt/EBITDA -0.60x
Debt/Equity 0.06x
Stability
100 /100
Stable Rev. volatility 4.26%
EPS volatility 12.10%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AKBLF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Peter Halling
Employees
2,721
Headquarters
Horsholm
Upcoming events
17 NOV
Earnings
Upcoming earnings report